Dynavax Technologies
Biopharmaceutical company discovering and developing novel products to prevent and treat infectious diseases.
Launch date
Employees
Market cap
€1.3b
Enterprise valuation
€866m (Public information from Sep 2024)
Share price
$11.21 DVAX
Berkeley California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 46.6m | 439m | 723m | 232m | 282m | 336m | 381m |
| % growth | 32 % | 844 % | 64 % | (68 %) | 21 % | 19 % | 13 % |
| EBITDA | (67.2m) | 142m | 298m | 21.0m | 1.3m | 28.4m | 41.6m |
| % EBITDA margin | (144 %) | 32 % | 41 % | 9 % | - | 8 % | 11 % |
| Profit | (75.2m) | 76.7m | 293m | (6.4m) | 25.7m | 51.0m | 67.8m |
| % profit margin | (162 %) | 17 % | 41 % | (3 %) | 9 % | 15 % | 18 % |
| EV / revenue | 10.5x | 3.4x | 1.9x | 5.7x | 3.2x | 2.4x | 1.8x |
| EV / EBITDA | -7.3x | 10.6x | 4.7x | 62.8x | 686.5x | 28.6x | 16.5x |
| R&D budget | 28.6m | 32.2m | 46.6m | 54.9m | - | - | - |
| R&D % of revenue | 61 % | 7 % | 6 % | 24 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$34.8m | Growth Equity VC | ||
| N/A | N/A | IPO | |
| N/A | $29.4m | Post IPO Equity | |
| N/A | $29.5m | Post IPO Equity | |
$30.0m | Post IPO Debt | ||
| N/A | $42.0m | Post IPO Equity | |
| N/A | $64.5m | Post IPO Equity | |
$40.0m | Debt | ||
* | N/A | $135m | Post IPO Equity |
* | N/A | $90.0m | Post IPO Equity |
| N/A | $80.8m | Post IPO Equity | |
| N/A | $175m | Post IPO Debt | |
* | N/A | $70.0m | Post IPO Equity |
| N/A | $80.5m | Post IPO Equity | |
$99.0m | Post IPO Debt | ||
* | $3.9m | Post IPO Equity | |
| Total Funding | €31.6m | ||
Related Content
Recent News about Dynavax Technologies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.